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http://www.biomedcentral.com/1471-2334/14/386RESEARCH ARTICLE Open AccessCytokine secretion from brain macrophages
infected with human immunodeficiency virus
in vitro and treated with raltegravir
Erick T Tatro1*, Benchawanna Soontornniyomkij1, Scott L Letendre2 and Cristian L Achim1Abstract
Background: Integrase inhibitors are a promising class of antiretroviral drugs to treat chronic human immunodeficiency
virus (HIV) infection. During HIV infection, macrophages can extravasate from the blood to the brain, while producing
chemotaxic proteins and cytokines, which have detrimental effects on central nervous system cells. The main goal of this
study was to understand the effects of raltegravir (RAL) on human brain macrophage production of immune-mediators
when infected with HIV, but did not compare with other antiretroviral agents.
Methods: Pro-inflammatory cytokines, IFN-γ, IL-10, IL-12-p70, IL-1, IL-8, TNF-α, and IL-6 were measured simultaneously in
tissue culture supernatants from primary brain derived macrophages, microglia. We tested the effects of RAL on markers
of astrocytosis and neurite integrity in primary human neuroglial cultures.
Results: RAL administered at 20 nM effectively suppressed HIV infection in microglia over 9 days. Only IL-8, IL-10, and
TNF-α were above the detection limit in the majority of samples and RAL significantly suppressed the rate of cytokine
production in HIV-infected microglia. During RAL-alone, the rate of IL-8 secretion was higher.
Conclusions: RAL did not affect neurite area but inhibited astrocyte growth in the neuroglial cultures. Exploring the
effects of RAL on pro-inflammatory molecule production in brain macrophages may contribute to designing ARV
neuroprotective strategies in chronic HIV infection.
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Chronic human immunodeficiency virus (HIV) infection
has detrimental effects on central nervous system (CNS)
neuronal health. The principal targets of productive HIV
infection in the brain are microglia and monocyte derived
macrophages [1-4]. In the periphery, HIV infection in
CD4 T cells is cytopathic, resulting in fast CD4 T cell
depletion [5], whereas in resting memory T cells, tissue
monocytes, macrophages, and brain microglia with in-
tegrated HIV survive longer and serve as an HIV reservoir
that persists indefinitely [6]. In adult humans, parenchy-
mal microglia are infrequently exchanged with peripheral
blood monocytes [7]. Perivascular cells in the CNS with
macrophage markers have a higher turnover and are* Correspondence: etatro@ucsd.edu
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unless otherwise stated.more frequently replaced by blood monocytes. Therefore,
perivascular brain macrophages may serve as a source
of HIV in the brain, and immunohistological and DNA
hybridization studies have confirmed the presence of
HIV proteins and DNA in these cells [8], which has
been shown to be associated with depleted pre- and
post- synaptic markers, synaptophysin and microtubule
associated protein-2 (MAP2) [9].
HIV effects on the CNS have behavioral consequences.
Neurocognitive impairment in HIV infected individuals
is associated with elevated viral load and microglial acti-
vation [10,11]. There are several prevailing hypotheses
for the mechanisms of neural damage in HIV: direct
neurotoxic effect from viral proteins and neural damage
via intracellular signaling and secondary neural damage
from cytokines and chemokines from infected microglia
and brain macrophages [12]. Drugs used to treat HIV
have variable neurotoxic effects, as examined by MAP2td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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reduction in MAP2 area. Of six combination regimens
which included protease inhibitor, non-nucleoside reverse
transcriptase inhibitor, and reverse transcriptase inhibitor,
four caused significant reduction in neuronal MAP2 area
[13]. As new antiretroviral drugs become available, it is
important to continue assessing neurotoxicity.
Integrase inhibitors are a relatively new class of anti-
retroviral compounds, one of which is raltegravir (RAL),
which has potent and durable antiviral activity similar to
that of efavirenz, but which achieved HIV suppression to
below detectable limits at a faster rate in a 24 week study
[14]. HIV integration into the host genome is a multistep
process involving: a) 3′ endonucleolytic cleavage of the
3′ end of DNA in the HIV pre-integration complex to a
conserved CA dinucleotide, b) Strand-transfer involving
concerted cleavage of host DNA and ligation of viral 3′
DNA to 5′ staggered site on host DNA, and c) DNA
repair of gaps and DNA synthesis. RAL functions by
inhibiting the strand-transfer step [15], thus preventing
the induction of DNA repair machinery which is associ-
ated with innate immune activation and cell death [16].
We were therefore interested in determining the CNS
efficacy of RAL by assessing: 1) neurotoxicity using in vitro
neuronal cultures following methods comparable to a
previous study [13], 2) inhibition of HIV infection in
cultured microglia, and 3) cytokine production in RAL-
treated, HIV infected microglia.
In primary human neuroglial cultures, we found that
RAL is not neurotoxic and we present evidence for reduced
astrogliosis. In primary human HLA-DR-positive brain
macrophages and microglia, we measured secretion of
seven cytokines across 9 d of in vitro HIV infection, and
found reduced rate of TNF-α, IL-10, and IL-8 production
in those treated with 20 nM RAL.
Methods
Cell culture
This study was approved by University of California San
Diego Human Research Protections Program. Microglia
were isolated through differential adhesion procedure
from fetal human brain tissue from elective terminated
pregnancy between 12 and 16 weeks of gestation [17], ac-
quired from Advanced Bioscience Resources, donors gave
written informed consent for research-use of the cells and
tissue. Single-cell suspension of central nervous system
cells were plated at 108 cells/mL in a 125 cm2 flask and
after 7 d, microglia removed by agitation and withdrawal
of nonadherent cells which were plated in selection media
on coverslips coated with poly-L-lysine (Life Technologies
P4707, Carlsbad, CA, USA). Microglia media compo-
nents were purchased from Life Technologies and consisted
of DMEM (11965–092), supplemented with glutamax
(35050–061), and gentamicin sulfate (15710–064). After4 d in culture, cells were differentiated with granulocyte/
macrophage colony stimulating factor (GM-CSF, Fisher
Scientific, 5056909) for 1 d. Thereafter, no media contained
GM-CSF. Microglia were inoculated with a seed stock of
HIVBa-L (5,000 pg/mL HIV p24) in fresh media for 4 hr,
then media changed in the presence and absence of 20 nM
RAL and maintained without media changes for 9 d. The
following reagents were obtained through the NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH: HIV-
1Ba-L from Dr. Suzanne Gartner, Dr. Mikulas Popovic
and Dr. Robert Gallo [18] and RAL (Cat # 11680) from
Merck & Company, Inc. All experimental conditions
were performed with three independent replicates.
Aliquots of 60 μL supernatant were removed every
48 hr starting 1 d after infection and stored with 2.5 μL
25X Complete protease inhibitor (Roche 04693116001,
Indianapolis, IN, USA) and stored at −80°C to measure
cytokine production. The 60 μL was replaced with fresh
media (no GM-CSF supplemented) to maintain a constant
500 μL per well. To verify HIV infection, a 200 μL aliquot
of supernatant was removed and replaced with fresh
media for HIV p24 ELISA at 1 d of infection and at the
endpoint (9 d) (Advanced Bioscience Laboratories, Inc.
5421, Rockville, MD, USA). After 9 d, cells were fixed
in 4% paraformaldehyde (Electron Microscopy Sciences
15710-S, Hatfield, PA, USA) for microscopy.
To assess for cytotoxicity, 25 μL supernatant at endpoint
(9 d) was used to measure lactate dehydrogenase (LDH)
activity following manufacturer’s instructions of CytoTox
96 Non-radioactive Cytotoxicity Assay (Promega, Madison,
WI, USA). Percent-cytotoxicity was calculated for each
condition by comparing to LDH activity of supernatant
from cells lysed in 0.1% Triton-X 100 for 1 hr.
Neuronal cultures were generated according to a proto-
col first described by White et al. [19] and modified for
our current usage exactly as described by Nguyen et al.
[20] from donated fetal human brain tissue from elective
terminated pregnancy between 12 and 16 weeks of gesta-
tion. Single-cell suspension of central nervous tissue were
plated at 105 cells/mL on glass coverslips coated in poly-
L-orinithine and laminin in 24 well-plates. Cultures were
mixed neuron - glia culture composed of approximately
60% neurons and 40% astrocytes. After 28 d in culture,
neurons were exposed to 20 and 100 nM RAL overnight
following by fixation and microscopy analysis.
Microscopy
Cells were fixed in 4% paraformaldehyde for 10 min at
37°C and washed 3 times in Tris buffered saline (PBS).
Cells were permeablized and non-specific antigen blocked
using 0.2% Triton X-100 and 2% fetal bovine serum for
2 hr, then incubated overnight with primary antibody at
4°C. After washing 3 times in TBS-T (0.2% Tween-20),
secondary antibodies were incubated at 1:750 dilution
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final wash in distilled water, then finally mounted on
glass slides with Vectashield with DAPI mounting media
(Vector Labs H-1500, Burlingham, CA, USA). Images
were captured by laser scanning confocal microscopy
at 40X magnification for quantification, images were
captured for 10 random fields per coverslip. The
imaging conditions were maintained exactly the same
across the different experimental conditions (separately
for measuring β-III tubulin, GFAP, or NF-κ-B). The fol-
lowing primary antibodies were used, diluted in blocking
buffer: mouse anti β-III tubulin (1:400) (R&D Systems
MAB1195, Minneapolis, MN, USA), rabbit anti glial
fibrillary acidic protein (GFAP) (1:5,000) (Dako, Z0334,
Glostrup, Denmark), rabbit anti phospho-NF-kB (1:200)
(Cell Signaling Technologies 3033, Billerica, MA, USA),
and mouse anti HLA-DR (1:200) (Abcam ab17101,
Cambridge, MA, USA). Secondary antibodies used were
the following: Alexafluor-568 conjugated sheep anti mouse
IgG (Life Technologies 11031) and Alexafluor-488 conju-
gated donkey anti rabbit IgG (Life Technologies 21206).
For image quantification of neuronal cultures, methods
were adapted from White et al. [19], green (β-III tubulin)
and red (GFAP) channels were separately measured by
setting a signal threshold and determining the area
covered, representing neurite density for β-III-tubulin,
and astrogliosis for GFAP. To quantify nuclear transloca-
tion of NF-kB, methods were adapted from Tatro et al.
[21], the cells were delineated by creating a mask for the
HLA-DR signal representing the cell bodies and the nuclei
were delineated by creating a mask for the DAPI signal.
The NF-kB signal was calculated for the cell body and the
nuclei by total signal intensity, and then the percent-
nuclear and percent-cytoplasm were calculated.
Cytokine production assays
Cytokines and chemokines were measured in tech-
nical duplicate and biological triplicate using 25 μL
aliquots following manufacturers instructions of a 7-plex
pro-inflammatory cytokine quantitation kit (Mesoscale
Discovery K15008B, Rockville, MD, USA), measured
on a Sector Imager 2400 instrument, and concentra-
tion determined from a manufacturer-supplied standards
(Mesoscale Discovery C0049-2). The following molecules
were quantitated: IFN-γ, IL-1β, IL-10, IL-12 p70, IL-6, IL-
8, and TNF-α.
Statistical analysis
For GFAP and β-III tubulin comparisons, Student’s t-test
was used to compare RAL vs Control of area covered.
For NF-kB measurements, percent nuclear was arcsine-
transformed (to account for upper and lower limits,
0-100%) and each condition compared by Student’s t test.
For cytokine production, linear regression using LeastSquares of concentration vs. time for each condition
(Control, HIV, RAL, HIV + RAL) was calculated (fitted
to Equation 1), including an interaction term. Equation
1: [Cytokine] = β0 + β1Time + β2Condition + β3Condition*-
Time, we tested for effects of time (rate of secretion), main
effect of Condition, and a Condition × Time interaction.
β3 corresponds to the effect that a given condition has on
the cytokine secretion compared to the null hypothesis,
P-values reported to test for a Condition × Time inter-
action is the probability that rate is the same for all
conditions together. The rates of cytokine production
(pg/mL⋅d) for each treatment condition were compared
to Control by Dunnett’s test.
Results and discussion
In this study, we measured cytokine secretion from
human microglia under four conditions, 1) No-treatment
control, 2) Infected with HIV, 3) Infected with HIV but
treated with 20 nM RAL, and 4) 20 nM RAL alone. The
concentration of 20 nM RAL was chosen on the basis of
evaluating several pharmacokinetics studies. The mean
trough plasma concentration from RAL once-daily parma-
cokinetics studies was 40 nM [22], while an independent
study calculated a CSF:Blood Plasma ratio of 0.058 with a
median (over 24 hr) plasma concentration 540.7 nM
(31.36 nM in CSF) [23]. One additional study evaluated
intracellular RAL concentration and calculated a 24 hr
area under the curve (AUC) 1,884 nMxh [24], which is
averages to roughly 78.5 nM. Therefore 20 nM RAL
seemed to be a reasonably relevant concentration to assess
in vitro effects on microglia.
We found that RAL administered at 20 nM was effect-
ive at suppressing HIV infection in microglia (Figure 1)
for at least 9 d. Only IL-8, IL-10, and TNF-α were above
the detection limit. We calculated the rate of cytokine
production for all three cytokines across the different
treatment groups (Table 1). The mean IL-8, IL-10, and
TNF-α concentrations and linear regression, separated
by conditions are shown in Figure 2. For IL-10, IL-8 and
TNF-α, there was a significant effect of RAL on the cyto-
kine production in the context of HIV infection. Alone,
the RAL-treated microglia had the highest concentration
of IL-8, IL-10, and TNF-α. However, in the context of
HIV infection, RAL-treated microglia had lowest pro-
duction of TNF-α and IL-8. This makes sense because
TNF-α autocrine signaling leads to IL-8 production via
NF-kB. However, it is important to note that the highest
production of TNF-α was in the presence of RAL alone
(Table 1). IL-8 and IL-10 production were lowest in
RAL treated microglia in the context of HIV, but not
significantly different among the other groups (Table 1).
It is remarkable that HIV and RAL alone induced cyto-
kine expression, but in combination, was below control
levels. This implies that RAL may be pro-inflammatory
p2
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Figure 1 HIV p24 measured in supernatant. Microglia were exposed
for 4 hr to stock HIVBaL virus (equivalent to 5,000 pg/mL of p24), then
washed in PBS. Aliquots of extracellular supernatant were then removed
immediately (day 1 on plot) and after 9 d in culture, then p24 measured
by ELISA. Plotted are means of three biological replicates with standard
deviation. ND— not detected. P24 was was significantly higher in HIV +
than HIV + RAL at 9 d (P < 0.001), and HIV + RAL was not significantly
different from uninfected at 9 d (P = 0.19), by ANOVA and Tukey
Honestly Significant Difference test.
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anti-inflammatory. One possibility is off-target effects on
DNA-binding proteins, mimicking NF-kB - like activation,
however in the presence of HIV-replication complex, it is
bound and not interacting with off-target proteins.
We assessed cytotoxicity through measuring LDH-
release in HIV-infected cells exposed to RAL and found
background levels cytotoxicity due to HIV-infection,
which was neither enhanced or diminished by RAL. The
mean ± standard deviation cytotoxicity in HIV-alone was
43 ± 7.9%; and for HIV + RAL was 45 ± 3.2%. This may
have been due to the protocol, which was acute infection
via exposure to high levels of HIV for 4 hr, followed by
media change including the drug. RAL may have sup-
pressed further integration and infection of more cells
with HIV, but it did not prevent lysis/death of those
already infected.
Activation of the IL-8 gene is enhanced by signaling
from NF-kB, and based on reduced IL-8 secretion in the
HIV + RAL treated cultures, we hypothesized lower NF-
kB activation and quantitated the nuclear translocationTable 1 The rate of cytokine secretion +/− standard error
over 9 days by microglia infected with HIV and / or
treated with 20 nM RAL (pg ×mL−1 × day−1)
Condition TNF-α IL-10 IL-8
Control 3.09 ± 1.8 1.2 ± 0.16 245 ± 6.2
HIV 5.54 ± 1.8 1.07 ± 0.12 232 ± 8.1
RAL 10.9 ± 3.8 1.25 ± 0.15 268 ± 9.9
HIV + RAL 2.2 ± 1.0 0.33 ± 0.14 132 ± 5.0
aP-value 0.04 < 0.001 < 0.0001
aFor a significant effect of treatment Condition on the rate of cytokine
secretion against the null hypothesis that all treatments were the same.of NF-kB after 9 d infection, we calculated the percent-
nuclear NF-kB compared to total NF-kB. The proportion
of NF-kB localized to the nucleus was significantly lower in
the HIV + RAL than the HIV + alone. Nuclear localization
of phosopho-NF-kB was quantitated as percent-nuclear,
then arcsine transformed for comparison by Dunnett’s test
vs. Control. RAL alone (21%) and HIV + RAL (22%) were
not significantly different from Control (20%), while HIV +
alone was significantly higher from Control (28%, P = 0.02).
There are several cellular markers of neurons and
astrocytes in cell culture, one of which is class-III β-
tubulin, a structural microtubule protein specifically
expressed in the cell body, axon, and dendrites of neur-
onal cells. To determine the neurotoxicity, we measured
the area of coverage of β-III tubulin, similar to Robertson
et al. [13], because retraction or loss of neurites would be
detected by this method. In order to measure the relative
amount of astrocytes in the culture, we similarly measured
the area covered by the astrocyte-specific protein, GFAP.
Diffuse astrocytosis was observed during HIV associated
dementia and HIV-encephalitis [25], and in the CNS of
transgenic mice expressing HIV proteins [26] and is a
marker of astrogliosis or astrocytosis. In the absence of
RAL, neuronal cultures had 110 ± 41 μm2 β-III tubulin
and 244 ± 49 μm2 GFAP. While with 20 and 100 nM
RAL, there was no significant effect on β-III tubulin, with
142 ± 48 and 89.4 ± 34 μm2, respectively, with P = 0.17
and P = 0.43 as assessed by Dunnett’s test vs. Control.
However, with 20 and 100 nM RAL, there was a signifi-
cant effect on GFAP, with 107 ± 26 and 115 ± 163 μm2,
respectively, with P = 0.0094 and P = 0.01 as assessed by
Dunnett’s test vs. Control. Thus, RAL had no significant
effect on β-III tubulin area at 20 or 100 nM and an inhibi-
tory effect on GFAP area. The possibility that RAL is toxic
to astrocytes should be noted, considering the important
role that they play in maintaining the blood brain bar-
rier and neuronal maintenance. Figure 3 shows the
quantitation of β-III tubulin and GFAP area as well as
representative photomicrographs.
The CNS has been proposed as a compartment for a
latent HIV reservoir which has long-term neurological
effects with downstream neurocognitive consequences,
attributed to cytokine production by infected perivascu-
lar CNS macrophages and parenchymal microglia [10].
Therefore, understanding whether antiretroviral com-
pounds themselves are neurotoxic becomes important
when infected individuals are on therapy for decades.
The purpose of the present study was to assess whether
RAL, an inhibitor of strand-transfer, has neurotoxic
properties and whether RAL slows the rate of cytokine
secretion by HIV infected microglia. We found that
RAL is not neurotoxic at 20 or 100 nM and that it sig-
nificantly inhibits cytokine secretion in HIV infected
microglia in vitro.
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Figure 2 (See legend on next page.)
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Figure 2 IL-8, IL-10, TNF-α, IL-6, IFN-γ, IL-1β, and IL12p70 production in supernatant of microglia during 9 d in culture. Microglia were
infected with HIV or not, and exposed to 20 nM RAL immediately afterwards (RAL, HIV + RAL), and a non-treated culture from the same source
grown alongside (Control). Supernatants were withdrawn and cytokines measured by Mesoscale Discovery 7-plex pro-inflammatory cytokine kit.
Plotted are concentrations (pg/mL) vs. Time after infection, separated by treatment group, error bars indicate standard deviation of biological
triplicates, dotted horizontal line indicates detection limits. Based on Standard Least Squares linear regression, RAL-treatment in HIV-infection
significantly reduced the secretion rate of IL-8, IL-10, and TNF-α. In RAL-alone, there was higher TNF-α and IL-6 at day 8.
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human neurons caused statistically significant reduction
of MAP2, a dendritic marker of mature neurons, when
exposed to some antiretroviral drugs. Individually, aba-
cavir, 2′,3′-dideoxyinosine, and nevirapine are predicted
to have relatively high risk of neurotoxicity, with at least
a 10% drop in MAP2 intensity at observed typical cere-
brospinal fluid (CSF) concentrations of the drugs [13].
Median RAL concentration in the CSF of treated HIV
patients was observed to be 14.5 ng/mL (30.05 nM) [23],
which is within range of the concentrations we tested for
neurotoxicity. This suggests that RAL has relatively low
neurotoxic risk.
We measured cytokine production by withdrawal of
supernatant from infected microglia cultures and quanti-
fication using a multiplex assay and found production
of IL-8, IL-10, and TNF-α, which increased linearly.
RAL on its own caused significant increase in the rate
of production of these three cytokines, mainly IL-10, an
anti-inflammatory cytokine; but resulted in a significant
decrease when administered with HIV. The most abundant
was IL-8, a molecule with potent chemotaxic properties
for neutrophils [27] and monocytes [28]. IL-8 gene tran-
scription is induced by NF-kB activation and nuclear
translocation, and is dependent on TNF-α. One preliminary
positron emission tomography (PET) study found slightly
increased retention of the PET ligand 11C-PK11195, which
binds to activated microglia, in neurologically asymptom-
atic and ARV-treated HIV-infected individuals [11].
One human study assessed IL-8 concentration in CSF of
patients with HIV associated dementia compared to HIV-
infected patients with no neurocognitive impairment and
found higher IL-8 in CSF of those with dementia [29]. In
our experiments, phospho-NF-kB nuclear translocationFigure 3 Primary human neuron-glia cultures exposed to RAL. (A) Qu
neuron - glia cultures exposed to 0, 20, and 100 nM RAL for 15 hr. Represe
100 nM RAL. Cultures were maintained for four weeks in neurobasal media
and stained for β-III tubulin (green) and GFAP (red) to illustrate neurons an
fluorescence microscopy under 40X objective magnification and quantifiedwas significantly higher only in the HIV-infected cultures,
not in Control, RAL-alone, or HIV + RAL.
We also observed production of IL-10, an anti-inflam-
matory cytokine which inhibits T cell proliferation and
is putatively produced early in HIV infection via NF-kB
signaling [30], which would be an antiviral action,
allowing the incipient reservoir to avoid detection.
In comparison with nucleoside reverse transcriptase
inhibitors, tenofovir and zidovudine, RAL has relatively
modest effects on monocyte cytokine production. Zidovu-
dine dose-dependently increased secretion of IL-8 and
tenofovir decreased it. Likewise, the anti-inflammatory
IL-10 was reduced in the presence of tenofovir while
zidovudine did not affect it [31].
One possible explanation for reduced TNF-α, IL-8,
and IL-10 production in our cultures is simply due to
fewer infected cells. Another possible explanation is that
inhibition of the strand transfer step of HIV integration
prevents the DNA damage and repair process from being
initiated, which may lead to downstream microglial activa-
tion. One weakness to the present study is the lack of
comparison with another antiretroviral compound or lack
of testing for combinations. Additionally, with measuring
the cytokines at one-day intervals, it is difficult to deter-
mine the order of events except by interpolating from
what is already known. An important future experiment
would be to assess the effect of conditioned media from
brain macrophage cultures on neuronal and glia cultures.
Conclusions
Results from this study suggest a low probability for
neurotoxicity of RAL and likely neuroprotective effect
in HIV-infection by suppressing the production of che-
motaxic inflammatory cytokine, IL-8.antification of area of β-III-tubulin (average area, μm2), and GFAP in
ntative images of cultures treated with (B) Control, (C) 20 nM, and (D)
on glass coverslips then exposed to RAL overnight, cells were fixed
d astrocytes, respectively. Ten images were acquired by deconvolution
using Image Pro Plus.
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